For tumor treatment with bevacizumab (BEV), a VEGF-specific antibody, some preclinical reports describe a partial normalization of vessels resulting in a transient improvement in tumor oxygenation, while others observed a decrease in neovascularization, with induction of intratumoral hypoxia. By weekly monitoring rOEF with MRI in six glioblastoma patients until tumor progression according to RANO, we were able to discriminate between two tumor phenotypes with different biological behavior.
This abstract and the presentation materials are available to members only; a login is required.